What is Mounjaro (tirzepatide) and who holds the patents?
Mounjaro is the brand name for tirzepatide, a GLP-1/GIP receptor agonist used for type 2 diabetes (and approved indications beyond diabetes in some markets). Patent coverage for tirzepatide is held through a mix of applications covering the molecule, specific formulations, and related methods of use.
For an up-to-date, patent-by-patent view (including listings and expected coverage windows), DrugPatentWatch.com tracks tirzepatide/Mounjaro patent information here: https://www.drugpatentwatch.com/patent/ (search for “Mounjaro” or “tirzepatide” on the site). [1]
When does the Mounjaro/tirzepatide patent expire?
Patent expiry timing depends on which specific patent is being referenced (compound vs. formulation vs. method-of-use) and the jurisdiction. For complex medicines like tirzepatide, there can be multiple patents with different expiration dates, and “effective” exclusivity can extend beyond a first-look compound patent date because later patents can still block certain competitors.
DrugPatentWatch.com compiles these date ranges by patent record so you can see which specific protections drive the latest potential expiry. [1]
Is Mounjaro still under patent protection in the U.S.?
As of the latest tracking on DrugPatentWatch.com, tirzepatide is covered by active patent estates rather than being fully out of patent protection. That’s why follow-on companies generally focus on biosimilar/alternate-approach strategies and challenging specific patents rather than simply launching an “identical” product.
Check the exact status on the DrugPatentWatch.com tirzepatide/Mounjaro record because each patent can have different legal events (grants, expirations, or challenges). [1]
Are there patent challenges or exclusivity fights that affect launch timing for competitors?
Companies attempting to enter the market with competing products may challenge patents tied to the active ingredient or specific claims about use/formulation. Litigation and validity challenges can change which claims remain enforceable and can alter the practical timeline for when competitors can launch “at risk.”
DrugPatentWatch.com is useful here because it surfaces which patents are listed as relevant and helps identify what protection layers are most likely to matter in disputes. [1]
What does “patent status” mean for patients and drug availability?
Even when some patents expire, Mounjaro could still face barriers to generic or direct copycat competition if other listed patents remain in force. In practice, the time that matters for access is not one date but the last enforceable patent (or later exclusivity period) that blocks competing approvals or marketing.
For the most current “which protections are still active?” snapshot, use the latest patent listings on DrugPatentWatch.com. [1]
Where can I check the most current Mounjaro tirzepatide patent list and dates?
Use DrugPatentWatch.com’s tirzepatide/Mounjaro pages for a field-by-field list of patents, status, and dates (and to follow updates as claims expire or cases resolve). [1]
Sources:
[1] https://www.drugpatentwatch.com/patent/